Pain sensitization, such as that experienced by patients with carpal tunnel syndrome (CTS), has been associated with poorer clinical outcomes after surgery. New research has found that, although pain sensitization in CTS patients correlates with preoperative symptom severity, CTS symptoms did not have a persistent effect on functional outcomes after surgery…
Search results for: back pain
Pain Response to Low Intensity Pressure Tied to Cognitive Deficits in Fibromyalgia
A recent study found that the perception of experimentally induced pain is closely associated with neurocognitive symptoms, such as attention, memory and executive function, in fibromyalgia patients. Specifically, fibromyalgia patients described low-intensity pressure as more painful than controls did…
Delayed Care: Research Paints Complex Picture of Treatment Delays
AMSTERDAM—A variety of factors lead to delays in patients seeking medical care for rheumatoid arthritis—from the nature of symptoms to coping tendencies—requiring more awareness from physicians when managing patients, researchers said at EULAR: the Annual European Congress of Rheumatology. Longer delays in treatment bring about more emotional distress to patients, missed chances to ease symptoms…
The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
The FDA has not approved extended release Remoxy, a gel capsule formulation of oxycodone, concluding that its potential benefits do not outweigh its risks…
Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis
New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…
Insys to Pay $150 Million to Settle U.S. Opioid Kickback Probe
(Reuters)—Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication. The tentative deal announced by the Arizona-based drugmaker marked a major step in Insys’ efforts to resolve an…
Pfizer-Lilly Pain Drug Meets Late-Stage Trial Goals
(Reuters)—An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. Opioid abuse has reached epidemic proportions in the United States and drugmakers have been looking for less addictive…
Don’t Rule Out Placebos for Osteoarthritis Pain Control
CHICAGO—The placebo effect in treating pain in osteoarthritis (OA) should not be discounted, an expert said at the ACR State-of-the-Art Clinical Symposium in April. It’s especially important to accept the effect as real considering that trials of pain therapies in OA generate such high placebo effects (typically at least 40%) and that OA treatment options,…
FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…
IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval
In its first phase 3 clinical trial, intravenous tramadol has met its primary endpoint for relieving postoperative pain…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 156
- Next Page »